🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines Trump’s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines Trump’s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications
Company Directory/Biotech/AstraZeneca (Alexion)

AstraZeneca (Alexion)

Alexion, AstraZeneca's rare-disease group, maintains a major UK presence developing complement-based therapies for ultra-rare disorders.

London, United Kingdom 6,000 employees Est. 1992 Website ↗
Products & services
0
Certifications
0
Open roles
0
Articles published
1
Overview Milestones Leadership Products & services Certifications Partners Facilities Articles Claim this page
About the company

Alexion, AstraZeneca's rare-disease group, maintains a major UK presence developing complement-based therapies for ultra-rare disorders.

Sector
Biotech
Facilities
Markets served
Company milestones
No milestones listed yet — companies can add their history once they claim this page.
Leadership team
Corporate Executive Office

Corporate Executive Office

Global Leadership

Senior leadership directing R&D, commercial strategy, and biomanufacturing operations.
Products, services & capabilities
Biopharmaceutical R&D & Manufacturing
Core Capability

Biopharmaceutical R&D & Manufacturing

Advanced therapeutic development, sterile formulation, and quality assurance.

Certifications & awards
No certifications or awards listed yet — companies can add these once they claim this page.
Partners & clients
No partners or clients listed yet — companies can add these once they claim this page.
Facilities & lab gallery
Articles by AstraZeneca (Alexion)All coverage →
Editorially reviewed coverage mentioning this company.
Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines

Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines

Global equity markets open August 2026 on a historic high as rumored $400B AstraZeneca-BMS merger talks and C…

Is this your company?

Register to manage your profile, publish articles to our readers, list your product catalogue and post jobs — all from one dashboard.